The Relative Strength (RS) Rating for Amedisys headed into a new percentile Thursday, as it got a lift from 67 to 72.
Can You Really Time The Stock Market?
This unique rating measures market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the trailing 52 weeks compares to other publicly traded companies.
Decades of market research reveals that the best stocks tend to have an 80 or better RS Rating as they begin their biggest price moves. See if Amedisys can continue to show renewed price strength and clear that threshold.
Amedisys is building a consolidation with a 98.95 buy point. See if the stock can break out in volume at least 40% higher than normal.
While sales growth fell last quarter from 5% to 4%, the bottom line grew 21%, up from 2% in the prior report.
Amedisys earns the No. 6 rank among its peers in the Medical-Outpatient/Home Care industry group. Encompass Health, Fresenius Medical Care and BrightSpring Hlth Svcs are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
